source
- FDA approves Rasonque, first therapy targeting genetic cause of advanced pancreatic cancerThe U.S. Food and Drug Administration has granted approval to Rasonque, a drug from Revolution Medicines, for patients with advanced pancreatic cancer. The medicine, whose generic name is daraxonra…
- FDA approves Rasonque, first-in-class RAS inhibitor for metastatic pancreatic cancerThe U.S. Food and Drug Administration has approved Rasonque (daraxonrasib), a RAS inhibitor, for the treatment of metastatic pancreatic adenocarcinoma. Rasonque is a tablet taken once daily that t…